
Sean Mcgarry
Examiner (ID: 19573, Phone: (571)272-0761 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1809, 1805, 1674, 1621, 1624 |
| Total Applications | 1922 |
| Issued Applications | 1098 |
| Pending Applications | 296 |
| Abandoned Applications | 560 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19650083
[patent_doc_number] => 12171843
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-24
[patent_title] => Hybrid regulatory elements
[patent_app_type] => utility
[patent_app_number] => 16/968196
[patent_app_country] => US
[patent_app_date] => 2019-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 23
[patent_no_of_words] => 22075
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16968196
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/968196 | Hybrid regulatory elements | Feb 6, 2019 | Issued |
Array
(
[id] => 16939888
[patent_doc_number] => 11052103
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-06
[patent_title] => Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/267615
[patent_app_country] => US
[patent_app_date] => 2019-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 61085
[patent_no_of_claims] => 39
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267615
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/267615 | Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof | Feb 4, 2019 | Issued |
Array
(
[id] => 16824605
[patent_doc_number] => 20210139898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => STRUCTURAL DOMAINS OF ANTISENSE RNA MOLECULES UP-REGULATING TRANSLATION
[patent_app_type] => utility
[patent_app_number] => 16/967254
[patent_app_country] => US
[patent_app_date] => 2019-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12064
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16967254
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/967254 | Structural domains of antisense RNA molecules up-regulating translation | Feb 4, 2019 | Issued |
Array
(
[id] => 14743835
[patent_doc_number] => 20190255091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-22
[patent_title] => RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 16/267194
[patent_app_country] => US
[patent_app_date] => 2019-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -59
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267194
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/267194 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Feb 3, 2019 | Abandoned |
Array
(
[id] => 16619897
[patent_doc_number] => 20210038550
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => DISEASE DETECTION AND TREATMENT BASED ON TRIMETHYL-LYSINE LEVELS
[patent_app_type] => utility
[patent_app_number] => 16/965629
[patent_app_country] => US
[patent_app_date] => 2019-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24396
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -53
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965629
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/965629 | Disease detection and treatment based on trimethyl-lysine levels | Jan 31, 2019 | Issued |
Array
(
[id] => 14403945
[patent_doc_number] => 20190167816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-06
[patent_title] => METHODS FOR PREVENTING OR TREATING FIBROTIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/263406
[patent_app_country] => US
[patent_app_date] => 2019-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15786
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263406
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/263406 | METHODS FOR PREVENTING OR TREATING FIBROTIC DISEASES | Jan 30, 2019 | Abandoned |
Array
(
[id] => 17921653
[patent_doc_number] => 11464874
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-11
[patent_title] => Treating metastatic cancer and model systems for metastatic disease
[patent_app_type] => utility
[patent_app_number] => 16/263677
[patent_app_country] => US
[patent_app_date] => 2019-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 59
[patent_figures_cnt] => 74
[patent_no_of_words] => 12608
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263677
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/263677 | Treating metastatic cancer and model systems for metastatic disease | Jan 30, 2019 | Issued |
Array
(
[id] => 14868631
[patent_doc_number] => 20190284557
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-19
[patent_title] => DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/261181
[patent_app_country] => US
[patent_app_date] => 2019-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52873
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16261181
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/261181 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | Jan 28, 2019 | Abandoned |
Array
(
[id] => 14778615
[patent_doc_number] => 20190264205
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => Photoreversible Acylation Reagents
[patent_app_type] => utility
[patent_app_number] => 16/261422
[patent_app_country] => US
[patent_app_date] => 2019-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17049
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -53
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16261422
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/261422 | Photoreversible acylation reagents | Jan 28, 2019 | Issued |
Array
(
[id] => 17664177
[patent_doc_number] => 11357853
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Inhibition of a lncRNA for treatment of neuroblastoma
[patent_app_type] => utility
[patent_app_number] => 16/965876
[patent_app_country] => US
[patent_app_date] => 2019-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 37
[patent_no_of_words] => 7603
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965876
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/965876 | Inhibition of a lncRNA for treatment of neuroblastoma | Jan 23, 2019 | Issued |
Array
(
[id] => 14994361
[patent_doc_number] => 20190316138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
[patent_app_type] => utility
[patent_app_number] => 16/253180
[patent_app_country] => US
[patent_app_date] => 2019-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22219
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16253180
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/253180 | Oligonucleotide compositions with enhanced efficiency | Jan 20, 2019 | Issued |
Array
(
[id] => 18526475
[patent_doc_number] => 11713463
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-01
[patent_title] => Compositions and methods for increasing expression of SCN2A
[patent_app_type] => utility
[patent_app_number] => 16/962796
[patent_app_country] => US
[patent_app_date] => 2019-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10896
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962796
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/962796 | Compositions and methods for increasing expression of SCN2A | Jan 16, 2019 | Issued |
Array
(
[id] => 15210457
[patent_doc_number] => 20190367915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => Method for Assaying MicroRNA, Cancer Therapeutic Agent, and Medical Composition Containing Same for Cancer Therapy
[patent_app_type] => utility
[patent_app_number] => 16/241269
[patent_app_country] => US
[patent_app_date] => 2019-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14489
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16241269
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/241269 | Method for assaying MicroRNA, cancer therapeutic agent, and medical composition containing same for cancer therapy | Jan 6, 2019 | Issued |
Array
(
[id] => 15102661
[patent_doc_number] => 10472632
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-11-12
[patent_title] => Anti-connexin compounds targeted to connexins and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/241943
[patent_app_country] => US
[patent_app_date] => 2019-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 17
[patent_no_of_words] => 34235
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16241943
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/241943 | Anti-connexin compounds targeted to connexins and methods of use thereof | Jan 6, 2019 | Issued |
Array
(
[id] => 14227067
[patent_doc_number] => 20190125706
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-02
[patent_title] => TREATMENT AND DIAGNOSIS OF COLON CANCER
[patent_app_type] => utility
[patent_app_number] => 16/240123
[patent_app_country] => US
[patent_app_date] => 2019-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20362
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16240123
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/240123 | Treatment and diagnosis of colon cancer | Jan 3, 2019 | Issued |
Array
(
[id] => 14897565
[patent_doc_number] => 20190292548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => Methods Of Identifying And Treating Poor-Prognosis Cancers
[patent_app_type] => utility
[patent_app_number] => 16/230098
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230098
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/230098 | Methods of identifying and treating poor-prognosis cancers | Dec 20, 2018 | Issued |
Array
(
[id] => 18559972
[patent_doc_number] => 11725208
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-15
[patent_title] => Conjugated antisense compounds and their use
[patent_app_type] => utility
[patent_app_number] => 16/771620
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19914
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 193
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771620
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/771620 | Conjugated antisense compounds and their use | Dec 13, 2018 | Issued |
Array
(
[id] => 16686756
[patent_doc_number] => 20210069231
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => PHARMACEUTICAL CARRIERS CONTAINING miRNAs FOR USE IN THE TREATMENT OF RENAL CANCER
[patent_app_type] => utility
[patent_app_number] => 16/772280
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772280
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/772280 | Pharmaceutical carriers containing miRNAs for use in the treatment of renal cancer | Dec 13, 2018 | Issued |
Array
(
[id] => 14778627
[patent_doc_number] => 20190264211
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => MODULATION OF GENE EXPRESSION AND SCREENING FOR DEREGULATED PROTEIN EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 16/213535
[patent_app_country] => US
[patent_app_date] => 2018-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37882
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213535
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/213535 | Modulation of gene expression and screening for deregulated protein expression | Dec 6, 2018 | Issued |
Array
(
[id] => 15086955
[patent_doc_number] => 20190338288
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => MODULATION OF TMPRSS6 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 16/213242
[patent_app_country] => US
[patent_app_date] => 2018-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21857
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213242
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/213242 | MODULATION OF TMPRSS6 EXPRESSION | Dec 6, 2018 | Abandoned |